Actuate Therapeutics (ACTU) News Today $8.40 +0.87 (+11.55%) (As of 12/26/2024 05:36 PM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Actuate Therapeutics announces interim Phase 2 data of elraglusibDecember 18, 2024 | markets.businessinsider.comActuate Therapeutics Shares Rise 12% on Positive Phase 2 Trial to Treat Metastatic Pancreatic Ductal CancerDecember 17, 2024 | marketwatch.comActuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic CancerDecember 17, 2024 | globenewswire.comActuate Therapeutics announces new data from Phase 2 trial of elraglusibDecember 17, 2024 | tipranks.comActuate Therapeutics (NASDAQ:ACTU) Trading 0.8% Higher - Here's What HappenedActuate Therapeutics (NASDAQ:ACTU) Stock Price Up 0.8% - What's Next?December 17, 2024 | marketbeat.comActuate Therapeutics (NASDAQ:ACTU) Stock Quotes, Forecast and News SummaryDecember 13, 2024 | benzinga.comActuate Therapeutics to be Added to Russell 2000® IndexNovember 26, 2024 | finance.yahoo.comActuate Therapeutics added to Russell 2000 IndexNovember 26, 2024 | tipranks.comActuate Therapeutics to join Russell 2000 indexNovember 26, 2024 | seekingalpha.comActuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing SarcomaNovember 12, 2024 | finance.yahoo.comActuate Therapeutics: FDA Grants Pediatric-Disease Status to Ewing Sarcoma TreatmentNovember 12, 2024 | marketwatch.comActuate Therapeutics (NASDAQ:ACTU) Trading Down 2.8% - Should You Sell?Actuate Therapeutics (NASDAQ:ACTU) Shares Down 2.8% - Here's What HappenedOctober 31, 2024 | marketbeat.comActuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug DevelopmentOctober 29, 2024 | globenewswire.comActuate Therapeutics Inc ACTUOctober 9, 2024 | morningstar.comActuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β InhibitorSeptember 23, 2024 | finance.yahoo.comActuate Therapeutics' (NASDAQ:ACTU) Quiet Period Set To Expire on September 23rdActuate Therapeutics' (NASDAQ:ACTU - Get Free Report) quiet period will expire on Monday, September 23rd. Actuate Therapeutics had issued 2,800,000 shares in its IPO on August 13th. The total size of the offering was $22,400,000 based on an initial share price of $8.00. During the company's quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.September 16, 2024 | marketbeat.comActuate Therapeutics: Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue SarcomasSeptember 11, 2024 | finanznachrichten.deActuate Gets FDA Orphan Designation for Elraglusib in Soft Tissue SarcomasSeptember 11, 2024 | marketwatch.comActuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing SarcomaSeptember 9, 2024 | globenewswire.comActuate to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | globenewswire.comActuate therapeutics insider sells $150,000 worth of sharesAugust 18, 2024 | investing.comActuate Therapeutics Inc (ACTU)August 17, 2024 | investing.comActuate Therapeutics (NASDAQ:ACTU) Insider Todd S. Thomson Sells 18,750 SharesAugust 17, 2024 | insidertrades.comBuy Rating Affirmed for Brainstorm Cell Therapeutics Amid Strategic Advances and Robust FinancialsAugust 16, 2024 | markets.businessinsider.comActuate Therapeutics, Inc. Common stock (ACTU)August 15, 2024 | ca.finance.yahoo.comActuate Therapeutics (NASDAQ:ACTU) Major Shareholder Leslie W. Kreis Sells 24,999 SharesAugust 15, 2024 | insidertrades.comActuate Therapeutics Announces Closing of Initial Public OfferingAugust 14, 2024 | globenewswire.comActuate Therapeutics Announces Pricing of Initial Public OfferingAugust 12, 2024 | globenewswire.com Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles." And if you’d like to get your hands on this, here you go, the complete breakdown. ACTU Media Mentions By Week ACTU Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACTU News Sentiment▼1.890.62▲Average Medical News Sentiment ACTU News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACTU Articles This Week▼31▲ACTU Articles Average Week Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MREO News Today CRMD News Today XERS News Today PHAT News Today KOD News Today TERN News Today PROK News Today VERV News Today RNAC News Today PRTC News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACTU) was last updated on 12/27/2024 by MarketBeat.com Staff From Our PartnersTrading 5-7 Stocks to Profit $1,300 a Day?If you want a straightforward, faster, and potentially more reliable way to trade… Learn this strategy by w...Prosper Trading Academy | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this ...Crypto 101 Media | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
